Mesenchymal stem cells for acute graft-versus-host disease - Authors' reply

The Lancet

Volumn 372, Issue 9640, 2008, Pages 716-

  Blanc, K Le ^a   Fibbe, W ^b   Frassoni, F ^c   Locatelli, F ^d   Ringdén, O ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ACUTE GRAFT VERSUS HOST DISEASE; CELL PROLIFERATION; HUMAN; LETTER; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 50149094495     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61300-8     Document Type: Letter

References (4)

1. Karlsson H., Samarasinghe S., Ball L.M., et al. Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T cell responses. Blood 112 (2008) 532-541
2. Ortiz L.A., Gambelli F., McBride C., et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 100 (2003) 8407-8411
3. Tögel F., Hu Z., Weiss K., Isaac J., Lange C., and Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 289 (2005) F31-F42
4. Le Blanc K., Rasmusson I., Sundberg B., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363 (2004) 1439-1441